Get the Stockscreener App
0.5024
6.39%
-0.0343
After Hours:
.52
0.0176
+3.50%
Conduit Pharmaceuticals Inc stock is traded at $0.5024, with a volume of 466.25K.
It is down -6.39% in the last 24 hours and down -22.19% over the past month.
Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being prioritized by biopharmaceutical companies to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready for autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor, and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.
See More
Previous Close:
$0.5367
Open:
$0.52
24h Volume:
466.25K
Relative Volume:
0.09
Market Cap:
$6.18M
Revenue:
-
Net Income/Loss:
$-4.21M
P/E Ratio:
-9.1679
EPS:
-0.0548
Net Cash Flow:
-
1W Performance:
-7.82%
1M Performance:
-22.19%
6M Performance:
-95.22%
1Y Performance:
-99.83%
1-Day Range:
$0.4801
$0.5275
1-Week Range:
$0.4801
$0.5848
52-Week Range:
$0.4801
$350.00
Conduit Pharmaceuticals Inc Stock (CDT) Company Profile
Name
Conduit Pharmaceuticals Inc
Sector
Industry
Phone
(646) 491 9132
Address
4851 TAMIAMI TRAIL NORTH, NAPLES
Compare CDT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CDT
Conduit Pharmaceuticals Inc
|
0.5024 | 6.18M | 0 | -4.21M | 0 | -0.0548 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.58 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
254.16 | 26.92B | 3.81B | -644.79M | -669.77M | -6.24 |
Conduit Pharmaceuticals Inc Stock (CDT) Latest News
Conduit Pharmaceuticals Inc (CDT)’s highs and lows: A closer look at its stock price fluctuations - uspostnews.com
Short Interest in Conduit Pharmaceuticals Inc. (NASDAQ:CDT) Increases By 98.5% - Defense World
Keeping an Eye on Conduit Pharmaceuticals Inc (CDT) After Insider Trading Activity - knoxdaily.com
Conduit Pharmaceuticals Inc (CDT)’s Day in Review: Closing at 0.56, Up by 4.07 - DWinneX
Investor’s Delight: Conduit Pharmaceuticals Inc (CDT) Closes Weak at 0.65, Down -5.79 - DWinneX
Conduit Pharmaceuticals (NASDAQ:CDT) Stock Price Down 2.9% – Time to Sell? - Defense World
What Do Wall Street Analysts Think About Conduit Pharmaceuticals Inc (NASDAQ: CDT) Stock? - Stocksregister
Conduit Pharmaceuticals files to sell 2.1M shares of common stock for holders - MSN
Conduit Pharmaceuticals Inc’s latest rating changes from various analysts - knoxdaily.com
Are Conduit Pharmaceuticals Inc (CDT) shares a good deal now? - uspostnews.com
Market Resilience: Conduit Pharmaceuticals Inc (CDT) Finishes Weak at 0.62, Down -20.51 - DWinneX
CDT’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - investchronicle.com
CDTConduit Pharms Latest Stock News & Market Updates - Stock Titan
Conduit Pharmaceuticals Announces Leadership Changes - marketscreener.com
Conduit Pharmaceuticals Announces Novel Cocrystal Patent Filing For Vtama® - MarketScreener
Strategic Patent Filing Could Transform VTAMA's $233B Market Potential - Stock Titan
Conduit Pharmaceuticals Announces up to $1,000,000 Share Repurchase Program - The Manila Times
Conduit Pharmaceuticals expands partnership with Sarborg - MSN
Conduit Pharmaceuticals Expands Partnership with Sarborg Limited to Leverage Machine Learning Data Analysis for Pipeline Optimization - The Manila Times
Machine Learning Deal: How Conduit Pharma Plans to Revolutionize Drug Development - Stock Titan
Analyzing Conduit Pharmaceuticals (CDT) and Its Competitors - Defense World
Conduit Pharmaceuticals meets Nasdaq listing standards By Investing.com - Investing.com Australia
Conduit Pharmaceuticals meets Nasdaq listing standards - Investing.com
Conduit Pharmaceuticals Receives U.S. Patent Approval For Its Lead Asset Targeting Autoimmune Diseases - The Manila Times
Major Patent Win: Conduit's Autoimmune Drug Gets 20-Year Market Protection - Stock Titan
Conduit Pharmaceuticals Inc. (CDT) reports earnings - Quartz
CONDUIT PHARMACEUTICALS INC. SEC 10-K Report - TradingView
CONDUIT PHARMACEUTICALS INC- The GF Score's 5 Key Aspects of Analysis - GuruFocus.com
Conduit Pharma Highlights Progress In Lupus Studies, Phase II Trial For AZD1656 - Nasdaq
Conduit Pharmaceuticals progresses in autoimmune drug studies By Investing.com - Investing.com Australia
Conduit Pharmaceuticals progresses in autoimmune drug studies - Investing.com
Conduit Pharmaceuticals Provides Research and Development Update on Progress for Pipeline Assets AZD1656, AZD5658, and AZD5904 - The Manila Times
Conduit Pharmaceuticals Reports Significant R&D Advancements in Lupus Studies and Pipeline Development - Nasdaq
Conduit's Triple-Drug Pipeline Shows Promise for Lupus TreatmentMajor R&D Breakthrough - StockTitan
A closer look at Conduit Pharmaceuticals Inc (CDT)’s stock price trends - uspostnews.com
Conduit Pharmaceuticals Inc. (NASDAQ:CDT) Short Interest Update - The AM Reporter
Is Conduit Pharmaceuticals Inc. (CDT) the Best Micro Cap Stock to Buy Now? - Insider Monkey
Conduit Pharmaceuticals Gets Nasdaq Extension, Plans Capital Market Transfer - MarketScreener
Conduit Pharmaceuticals Provides Update on Nasdaq Stock Market Hearing Panel - The Manila Times
Conduit Pharmaceuticals secures Nasdaq extension - Investing.com
Conduit Pharmaceuticals Secures Extension for Nasdaq Compliance Following Bid Price Regaining - Nasdaq
Can Conduit Pharmaceuticals Keep Its Nasdaq Listing? Critical Deadlines Ahead - StockTitan
Conduit Pharmaceuticals secures Nasdaq extension By Investing.com - Investing.com Australia
Conduit Pharmaceuticals Inc (NASDAQ: CDT) Is Down -83.09% So Far This Year: What Will Happen Next? - Stocks Register
Taking a look at what insiders are doing to gauge the Conduit Pharmaceuticals Inc (CDT)’s direction - Knox Daily
Conduit Pharmaceuticals Inc (CDT) requires closer examination - uspostnews.com
Conduit Pharmaceuticals Advances Phase II AI Collaboration With Sarborg To Enhance Drug Development - Nasdaq
Conduit Progresses Phase II of its AI Initiative with Sarborg - The Manila Times
How Conduit's New AI System Could Revolutionize Drug Development Decision-Making - StockTitan
Conduit Pharmaceuticals Inc Stock (CDT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.39%
3.66%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):